Proteome Sciences Appoints Director of Personalised Medicine
News Oct 30, 2013
Chee Gee is a biomarker and translational medicine expert and was a former Biomarker and Experimental Medicine Leader for 5 years at Roche in multiple therapeutic areas including CNS, cardiovascular, respiratory and inflammation. Most notable was his role as the clinical oncology biomarker leader for the pivotal Phase III ToGA Herceptin trial and the co-development of the HER2 companion diagnostic in gastric cancer.
Prior to this Chee Gee spent 11 years at Glaxo Smith Kline where he was the European Therapeutic Area Analyst for Genetics Research reporting to Dr Allen Roses. He has specialist expertise in regulatory affairs and value-based drug pricing, reimbursement and market access.
Chee Gee’s role at Proteome Sciences will be to extend its business development strategy and to strengthen the commercial relationships with pharmaceutical, clinical and academic partners globally.
Commenting on his appointment Christopher Pearce, CEO of Proteome Sciences, said:
“We are delighted to have Dr See join our team at this important juncture in Proteome Sciences’ development as personalised medicine is bepcoming ever more critical in respect to disease diagnosis and prognosis, drug development and patient management. Chee Gee’s skills are perfectly suited to enhance our growing reputation in this crucial field of medicine”.
Dr See added:
“I have been extremely impressed with the outstanding and innovative science that underpins Proteome Sciences’ commercial strategy and its range of powerful platform technologies and solutions. These meet the growing needs of the healthcare industry from diagnostics through to therapeutics and patient care and management in a dynamic and rapidly changing market place. I really look forward to working with the team at Proteome Sciences to extend its leading reputation in the markets it serves and to drive growth and revenue.”
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE